Healthcare & Life Sciences

DEA: Mississippi Meth Dealer Sentenced to 10 Years

The DEA announced the sentencing of Anthony Russell, a Mississippi meth dealer, to 10 years in prison. This action is highlighted as a victory for public safety and the agency's mission to combat drug trafficking, particularly fentanyl.

USPTO Patent Application for Medical Testing and Treatment Protocols

The USPTO has published a patent application (US20260088141A1) for a system and method to determine medical testing and treatment protocols. The application, assigned to Intervention Insights, Inc., outlines a process for matching patient profiles to cohorts to identify appropriate tests and treatments.

USPTO Patent Application: Cordless Surgical Instrument Speed Limit

The USPTO has published a patent application from ConMed Corporation for a cordless surgical instrument designed to allow users to set and limit the maximum operating speed. This feature aims to enhance safety and precision during surgical procedures by enforcing a programmed speed limit.

USPTO Patent Application: Medical Ventilator Control Unit

The USPTO has published a new patent application (US20260083927A1) for a control unit for a medical ventilator. The application details a system designed to provide a respiratory air flow to a patient's respiratory apparatus.

Turf Toe Rehabilitation Device and Method Application

The USPTO has published a patent application for a turf toe rehabilitation device and method. The application details a device designed to assist patients in active and passive rehabilitation phases for metatarsophalangeal joint injuries, aiming to accelerate recovery.

USPTO Patent Application: Medicament Delivery Device Dosage Adjustment

The USPTO has published a patent application detailing a medicament delivery device that adjusts dosages based on a user's menstrual cycle phase. This technology aims to improve blood glucose control for users by reducing the risk of hyperglycemia and hypoglycemia.

USPTO Patent Application for Insulin Delivery Methods

The USPTO has published a patent application (US20260083910A1) detailing new methods, systems, and devices for insulin delivery. The application, filed on December 1, 2025, by inventors Bryan Mazlish and Lane Desborough, focuses on responsive basal insulin delivery rates and variable duration instructions for insulin delivery devices.

USPTO Patent Application: Dementia with Lewy Bodies Identification Method

The USPTO has published a patent application detailing a method for identifying Dementia with Lewy Bodies (DLB) using DNA methylation patterns. The application, filed by inventors from Spain, describes a diagnostic technique involving mitochondrial DNA analysis and provides for classification models, oligonucleotides, and kits.

USPTO Patent Application for Continuous Patient Authentication

The USPTO has published a patent application (US20260087119A1) for systems and methods related to continuous patient authentication. The application describes techniques for passive authentication using sensor data to allow access to medical device software without user prompts.

USPTO Patent Application: Radiation Dose Optimization for Particle Emitter

The USPTO has published a new patent application detailing a method for concurrent optimization of radiation doses for particle emitter devices across multiple treatment phases. The application, filed by Roni Hytonen, Perttu Niemelä, and Lauri Halko, aims to improve treatment efficacy by dynamically adjusting radiation doses based on phase-specific objectives.

USPTO Patent Application: Veterinary Orthopaedic Surgery Planning System

The USPTO has published a patent application (US20260083539A1) for a system and method for planning veterinary orthopaedic surgery. The application, filed by IN LIFE VET SA, describes a system for expanding bone implants to restore bone volume or geometry, utilizing a planning support with standardized fracture classifications.

USPTO Patent Application for Immunoconjugates

The USPTO has published a new patent application, US20260083855A1, filed by Hoffmann-La Roche Inc. The application relates to immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. This filing is part of the standard patent application process.

USPTO Patent Application: Antibody Conjugates with Bis-MSPT Linker

The USPTO has published a new patent application (US20260083854A1) detailing antibody conjugates that utilize a bis-MSPT linker. The application, filed by inventors Riazul Alam, Guillermo S. Cortez, and Yan Wang, describes pharmaceutical compositions and methods related to these conjugates.

USPTO Patent Application: CD70 Antibody Drug Conjugates

The USPTO has published a new patent application (US20260083853A1) detailing CD70 antibody drug conjugates for treating cancer and autoimmune diseases. The application was filed on October 25, 2023, by inventors Xiao Shang and others.

USPTO Patent Application for Peptoid Nucleic Acid Delivery

The USPTO has published a patent application (US20260083769A1) detailing novel hydroxyalkyl-capped cationic peptoids for nucleic acid delivery. The application, filed by inventors from various institutions, describes compositions and methods for delivering polyanionic compounds to cells and eliciting immune responses.

USPTO Patent Application: Phage T4 Nanoparticle Vaccine Platform

The USPTO has published a patent application (US20260083835A1) detailing a modular bacteriophage T4 nanoparticle vaccine platform. This platform is designed for the rapid development of dual COVID-19 and flu mucosal vaccines, administered intranasally without an adjuvant.

USPTO Patent Application: Engineered Probiotics Expressing Anti-Inflammatory Molecules

The USPTO has published a patent application (US20260083783A1) from the University of Cincinnati for engineered probiotics that express anti-inflammatory molecules. The application details a genetically modified E. coli bacterium designed to produce a microbial anti-inflammatory molecule (MAM) protein.

USPTO Patent Application for Generating CD4 T Cells

The USPTO has published a patent application (US20260083778A1) for methods of generating CD4 T cells from progenitor cells. The application, assigned to Boston Medical Center Corporation, describes a specific differentiation process for therapeutic use.

USPTO Patent Application: CARs for Hidradenitis Suppurativa Treatment

The USPTO has published a patent application (US20260083777A1) filed by Sonoma Biotherapeutics, Inc. The application describes chimeric antigen receptors (CARs) designed to target citrullinated polypeptides for the treatment of hidradenitis suppurativa.

USPTO Patent Application: Cancer Treatment with Anti-CD20 Antibody and Acylfulvenes

The USPTO has published a patent application (US20260083691A1) filed by Lantern Pharma Inc. The application describes a method for treating cancer by combining an anti-CD20 antibody with acylfulvenes. This patent application is related to novel therapeutic combinations for B-cell cancers.

USPTO Patent Application: Thiazolidine Linkers for Protein-Drug Conjugates

The USPTO has published a new patent application (US20260083856A1) detailing thiazolidine linkers for protein-drug conjugates and their uses in treating diseases. The application was filed on September 11, 2025, and is scheduled for publication on March 26, 2026.

USPTO Patent Application: Anti-DPP3 Antibody Formulations

The USPTO has published a patent application from 4TEEN4 Pharmaceuticals GmbH for formulations and dosage amounts for administering an anti-DPP3 antibody or fragment thereof to humans. The application, filed on August 26, 2025, details potential treatments for life-threatening circulatory failure conditions such as shock.

USPTO Patent Application: Recombinant Human Type III Collagen for Angiogenesis

The USPTO has published a patent application (US20260083883A1) detailing recombinant human type III collagen designed to promote angiogenesis. The application describes modifications to natural type III collagen to enhance its angiogenic function and adhesion properties, potentially increasing the angiogenesis rate by over 37%.

USPTO Patent Application: Compositions Targeting Endothelial Cells

The USPTO has published a patent application from Harvard College detailing novel compositions for targeting endothelial cells. These compositions, which include binders, linkers, and radioactive isotopes, are intended for selective delivery to cells and treating diseases, including cancer.

USPTO Patent Application: Sustained Transgene Expression of Modified ERT2 Peptide Fusion

The USPTO has published a patent application (US20260083859A1) detailing a novel fusion polypeptide for sustained transgene expression. The application, filed by inventors from various institutions, describes targeting constructs for inducible cell death systems using modified estrogen receptor ligand binding domains.

USPTO Patent Application for Capsid Polypeptides

The USPTO has published a new patent application (US20260083863A1) from Dyno Therapeutics, Inc. for capsid polypeptides designed for payload delivery. The application details specific polypeptide sequences and their methods of use in therapeutic applications.

USPTO Patent Application for CsgA-Derived Nanostructures for Antigen Delivery

The USPTO has published a patent application (US20260083834A1) for CsgA-derived nanostructures designed for antigen delivery. The application details self-assembling polypeptides conjugated to immunogens that form nanofilaments to stimulate immune responses, potentially for vaccines against various conditions.

USPTO Patent Application: Antibody Drug Conjugate Comprising NMT Inhibitor

The USPTO has published a new patent application (US20260083858A1) related to antibody drug conjugates (ADCs) that comprise an NMT inhibitor conjugated to an antibody via a linker. The application details the inventors and abstract of the invention.

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

USPTO Patent Application: IL-17 Antibody Compositions

The USPTO has published a patent application (US20260083842A1) detailing pharmaceutical products and stable liquid compositions of IL-17 antibodies, such as secukinumab. The application covers methods of making these compositions and their use in treating IL-17-mediated disorders, including autoimmune conditions like psoriasis and rheumatoid arthritis.

Bispecific Molecule Stabilizing Composition Patent Application

The USPTO has published a patent application (US20260083841A1) for a pharmaceutical composition designed to stabilize bispecific antigen-binding molecules at increased concentrations. The composition includes buffer agents, saccharides, and specific stabilizing agents like EDTA or citric acid.

USPTO Patent Application: NEO-201 Antibody for Suppressing Myeloid Derived Suppressor Cells

The USPTO has published a patent application (US20260083840A1) detailing methods for ablating myeloid derived suppressor cells using the NEO-201 antibody. The application describes the antibody's specific binding to certain O-glycans and its potential use in treating cancers and infectious diseases by suppressing gMDSCs.

USPTO Patent Application: Treating NSCLC with Dostarlimab or Biosimilar

The USPTO has published a patent application detailing a method for treating non-small cell lung cancer (NSCLC) using dostarlimab or a biosimilar. The application outlines a treatment approach for patients previously treated with an immune checkpoint inhibitor.

USPTO Patent Application: Modified Coronavirus Spike Antigen Protein

The USPTO has published a patent application (US20260083836A1) for a modified coronavirus spike antigen protein. The application describes a protein designed to suppress cell membrane fusion ability and improve safety by modifying cleavage sites, aiming to enhance vaccine efficacy and antibody production.

Emergency Sirens Test Scheduled for April 7

The Delaware Division of Public Health announced a scheduled test of emergency sirens for Tuesday, April 7, 2026, at 7:20 PM. This test is part of the state's emergency preparedness measures, particularly concerning the Salem/Hope Creek Nuclear Generating Station.

New Moon Senior Living Trademark Application Published

The USPTO has published the trademark application for "New Moon Senior Living" for opposition. The application, filed on March 24, 2026, covers assisted living facility services, including residential care for the elderly, respite care, and palliative care support.

USPTO Trademark Application for Cosmetic Services

The USPTO has received an intent-to-use trademark application for the mark TIIGRIS, filed on August 12, 2025. The application covers various cosmetic and medical camouflaging services. This filing indicates a potential new market entrant for these specialized services.

USPTO Intent to Use Trademark Application - Rinse Dental

The USPTO has received an intent-to-use trademark application for 'Rinse Dental' filed on August 12, 2025. The application pertains to dentistry services and is identified by application number TM99333900.

MYVAL TONE Trademark Application for AI Wellness Services

The USPTO has received an intent-to-use trademark application for 'MYVAGAL TONE' for AI wellness services, including software for stress measurement and health assessment, and wellness consulting. The application was filed on August 15, 2025.

Everwell Counseling Trademark Application Published for Opposition

The USPTO has published the trademark application for "Everwell Counseling and Consulting" for counseling services, including marriage, grief, and mental health counseling. The application was published for opposition on March 25, 2026, with a filing date of March 24, 2026.

USPTO Trademark Application - NO SHADE TAN CO

The USPTO has received an intent-to-use trademark application for the mark "NO SHADE TAN CO". The application covers a range of self-tanning and skin care products, as well as related services like online retail and spray tanning salons. The filing date for this application was March 24, 2026.

USPTO Trademark Application: Diabetes Reversal Alliance

The USPTO has received an intent-to-use trademark application for 'Diabetes Reversal Alliance' on March 24, 2026. The application covers various medical services, including diabetes treatment, telemedicine, wellness programs, and health information provision.

DEDICARE Trademark Application - Medical Services

The USPTO has received an intent-to-use trademark application for the mark DEDICARE. The application covers services including electronic health record management, telemedicine, medical billing support, and physician services. The filing date was August 15, 2025.

USPTO Trademark Application for Hair Care Products

The USPTO has received an intent-to-use trademark application for hair care products and related beauty consultation services. The application, filed on August 15, 2025, covers a range of hair care items including shampoos, conditioners, gels, sprays, serums, and emollients.

Revolution Medicines Trademark Renewal

The USPTO has renewed the trademark 'Revolution Medicines' (TM98222647) for pharmaceutical preparations and related services. The renewal is effective March 25, 2026, and covers services including drug discovery and providing medical information online.

DOVESONG RETREAT Trademark Application for Memory Care Services

The USPTO has received an intent-to-use trademark application for "DOVESONG RETREAT" for memory care and assisted living services. The application was filed on August 14, 2025, with an intended use date of March 24, 2026.

USPTO Trademark Application - ONCOCONNECTS for Cancer Consulting

The USPTO has received an intent-to-use trademark application from ONCOCONNECTS for consulting services related to cancer diagnosis and treatment. The application was filed on August 13, 2025, and is designated for Class 044, which covers medical services.

Breathíque Trademark Application - Intent to Use

The USPTO has received an intent-to-use trademark application for the mark "Breathíque" by an unspecified applicant. The application covers educational services, meditation training, meditation cushions, and wellness consulting.

STRIPIT Trademark Application - Medical Services

The USPTO has received an intent-to-use trademark application for the mark STRIPIT. The application covers services including a website featuring health and nutrition information, dietary and nutritional supplements, and online retail for wellness products. The filing date was August 14, 2025.

USPTO Trademark Application for CERV

The USPTO has received an intent-to-use trademark application for the mark 'CERV'. The application covers software as a service for enterprise resource planning and customer relationship management, as well as various services including lawn care, pest control, and property maintenance. The filing date was August 13, 2025.